To the full analysis
Carl Zeiss Meditec stock: growth
AFX.DECarl Zeiss Meditec reported $2.47B in revenue for fiscal 2025, up 7.8% on the prior year, up 10.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.6%
per year from 2006 to 2025, per share 5.8%
Earnings (Annual rate)
9.2%
per year from 2006 to 2025, per share 5.3%
Free cash flow (Annual rate)
6.1%
per year from 2006 to 2025, per share 2.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.8% | 7.9% | 9.6% |
| Revenue per share | 11.3% | 7.1% | 5.8% |
| Earnings | 2.9% | 8.5% | 9.2% |
| Earnings per share | 3.3% | 7.7% | 5.3% |
| Free cash flow | 5.0% | 15.6% | 6.1% |
| Free cash flow per share | 5.5% | 14.8% | 2.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $432.78M | $29.57M | $61.51M |
| 2007 | $631.28M | $55.01M | $54.77M |
| 2008 | $665.07M | $62.32M | $46.39M |
| 2009 | $709.28M | $61.06M | $78.64M |
| 2010 | $749.83M | $66.04M | $59.34M |
| 2011 | $840.82M | $74.14M | $34.41M |
| 2012 | $955.04M | $79.64M | $74.07M |
| 2013 | $1B | $102.09M | $59.82M |
| 2014 | $1.01B | $83.06M | $49.85M |
| 2015 | $1.15B | $69.03M | $44.29M |
| 2016 | $1.21B | $108.96M | $92.92M |
| 2017 | $1.32B | $148.98M | −$1.43M |
| 2018 | $1.42B | $140.13M | $168.93M |
| 2019 | $1.62B | $177.03M | $191.62M |
| 2020 | $1.48B | $135.61M | $147.98M |
| 2021 | $1.82B | $261.82M | $328.62M |
| 2022 | $2.11B | $325.68M | $117.71M |
| 2023 | $2.32B | $321.79M | $151.81M |
| 2024 | $2.29B | $198.05M | $105.4M |
| 2025 | $2.47B | $156.47M | $188.89M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.